Eli Lilly & Co. 2003 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2003. Eli Lilly and Company is a global pharmaceutical firm incorporated in Indiana, operating primarily in a single significant business segment: pharmaceutical products. The company discovers, develops, manufactures, and sells products in approximately 140 countries. While it maintains an animal health business, operations in this segment are not material to the financial statements. As of February 27, 2004, the company had approximately 1.13 billion shares of common stock outstanding with an aggregate market value of roughly $72 billion.
Key Financial Metrics
Note: Specific revenue, profit, and cash flow figures for 2003 are incorporated by reference from the 2003 Annual Report (Exhibit 13) and are not explicitly detailed in the provided text. The following metrics are available from the filing text:
- Research and Development (R&D) Expenses: $2.35 billion for 2003 (compared to $2.15 billion in 2002 and $2.24 billion in 2001).
- Employee Count: Approximately 46,100 total employees at year-end 2003, including 8,800 in R&D and 21,650 outside the United States.
- Major Customers: Three U.S. wholesale distributors (AmerisourceBergen, Cardinal Health, and McKesson) each accounted for between 15% and 16% of worldwide consolidated net sales in 2003.
- Debt Instruments: The company has registered various notes, including 8-3/8% Notes due 2006, 6.57% Notes due 2016, 7-1/8% Notes due 2025, and 6.77% Notes due 2036.
Material Changes and Operational Highlights
The company continued to invest heavily in R&D, increasing spending by approximately $200 million year-over-year. Key product developments and approvals in 2003 included:
- Neuroscience: Symbyax was approved in late December 2003 for bipolar depression.
- Other Pharmaceuticals: Cialis was launched in the U.S. in December 2003 via a joint venture with ICOS Corporation and approved in over 55 countries.
- Manufacturing Compliance: Following FDA observations in 2001 regarding Good Manufacturing Practices (cGMP), the company implemented comprehensive improvements. In late October 2003, the FDA advised that its Indianapolis facilities had reached a level of compliance allowing for preapproval site inspections.
Guidance, Risks, and Legal Proceedings
Legal and Regulatory Risks:
- Patent Litigation: The company is engaged in significant litigation regarding generic challenges to Zyprexa (Zenith, Dr. Reddy's, Teva) and Evista (Barr Laboratories). A trial for Zyprexa was held in early 2004, with a ruling expected in the second or third quarter. An unfavorable outcome could materially adversely impact operations.
- Product Liability: Lilly is a defendant in approximately 115 actions regarding diethylstilbestrol (DES) and approximately 315 actions involving thimerosal and autism claims. Additionally, there are approximately 15 cases alleging Zyprexa caused diabetes or high blood glucose.
- Government Investigations: The company is cooperating with investigations by the Department of Justice (regarding Evista marketing), the SEC (regarding Polish subsidiaries and the Foreign Corrupt Practices Act), and the FTC (regarding industry rebate practices).
Market Risks:
- Pricing Pressure: The company anticipates continued and intensifying pricing pressures due to the Medicare Prescription Drug, Improvement and Modernization Act of 2003 (MMA) and state-level cost containment measures.
- Intellectual Property: Key patent expirations are noted for Zyprexa (2011), Gemzar (2010), and Humalog (2013), though use patents may extend exclusivity for some products.
Investor Verification Checklist
- Verify the specific consolidated net sales, net income, and cash flow figures in the 2003 Annual Report (Exhibit 13), as these are incorporated by reference and not listed in the 10-K text provided.
- Monitor the outcome of the Zyprexa patent litigation trial, with a ruling expected in mid-to-late 2004, as this poses a material risk to future revenue.
- Review the status of government investigations (DOJ, SEC, FTC) to assess potential fines, penalties, or operational restrictions.
- Assess the impact of the Medicare Modernization Act (MMA) on future pricing strategies and volume growth starting in 2006.
- Confirm the progress of manufacturing quality improvements to ensure no further FDA regulatory actions are taken.